Skip to main navigation
logo

Investor Relations

  • Overview
  • News & Events
    • News Releases
    • Events & Presentations
  • Corporate Governance
    • Governance Overview
    • Management
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Quarterly Results
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Shareholder Services
    • Email Alerts
    • Contact IR
    • RSS Feeds

News Releases

27 Feb '23
Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy Filing
Test Delivers Lab-Quality Performance with Results in 30 Minutes or Less – The First At-Home Test to Ever Include Flu Lab-quality results for both COVID-19 and Flu now available at home from one single test COVID-19 and Flu have similar symptoms but different treatments, requiring a fast,
22 Feb '23
Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
No debtor-in-possession financing required as the Company intends to fund operations and the sale process with available cash on hand. EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company,
04 Jan '23
Lucira Health Launches Lucira Connect, a Free Test-to-Treat Telehealth Service for Covid-19 or Flu in Canada
For $98 CAD Canadians will receive a free telehealth appointment included with purchase of a test Lucira Connect provides lab-quality at-home test-users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only the cost of the test, excluding prescription costs.
03 Jan '23
Lucira Health Submits EUA for Over-The-Counter (OTC) Use of its COVID-19 & Flu Test
EMERYVILLE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test.

Investor Tools

  • Print Page
  • RSS Feeds
  • Email Page
  • Email Alerts

© 2023 Lucira Health, Inc. All rights reserved.

  • Facebook
  • Twitter
  • LinkedIn
  • Google+